Q1 2026 saw continued progress in veterinary cell therapy development, with key regulatory milestones for BCX-CM-J and BCX-CM-AD, strong cash reserves (PLN 60.8m), and no sales revenue as the company remains pre-commercial. Major investments in manufacturing and positive grant decisions support future growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.